Bringing the fundamentals into focus…
Back to Pacira BioSciences, Inc.
How Pacira BioSciences, Inc. stacks up
PCRX · against 453 other Healthcare companies of similar size
Valuation
53/ 100
Below the middle of the pack.
Ranked #228 of 454 · scores higher than 49% of peers
Bars: peers in each 10-point band of the valuation score38 peers with a valuation score of 50–59, including PCRX · Click a bar to see the companies
Why valuation scores 53?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- Earnings yield is close to the peer norm. Earnings yield: 1.0% vs peer median 1.5%
- more operating profit (EBITDA) for the company's total value: stronger than 72% of peers. EBITDA yield: 6.7% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 95% of peers. Free cash flow yield: 12.4% vs peer median 0.0%
Metric by metric
Position: dot = PCRX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | PCRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 442 reported | 1.0% | 1.5% | 44% | 30% | |
| EBITDA yieldHigher is better · 457 reported | 7.7% | 4.5% | 68% | 50% | |
| Free cash flow yieldHigher is better · 209 reported | 12.4% | -0.5% | 94% | 20% | |
| Book yieldHigher is better · 446 reported | 46.4% | 39.4% | 59% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around PCRXScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score